PMID- 23174198
OWN - NLM
STAT- MEDLINE
DCOM- 20130529
LR  - 20121231
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 31
IP  - 3
DP  - 2013 Jan 7
TI  - A PCV2 vaccine based on genotype 2b is more effective than a 2a-based vaccine to 
      protect against PCV2b or combined PCV2a/2b viremia in pigs with concurrent PCV2, 
      PRRSV and PPV infection.
PG  - 487-94
LID - S0264-410X(12)01623-4 [pii]
LID - 10.1016/j.vaccine.2012.11.030 [doi]
AB  - The predominant genotype of porcine circovirus (PCV) in the pig population today 
      is PCV2b yet PCV2a-based commercial vaccines are considered effective in 
      protecting against porcine circovirus associated disease. The objective of this 
      study was to compare the ability of PCV2a- and PCV2b-based vaccines to control 
      PCV2b viremia in a challenge model that mimics the U.S. field situation. 
      Sixty-three pigs were randomly assigned to one of eight groups. Sixteen pigs were 
      vaccinated with an experimental live-attenuated chimeric PCV1-2a vaccine based on 
      genotype 2a and another 16 pigs with a chimeric PCV1-2b vaccine based on genotype 
      2b. Challenge was done 28 days post vaccination (dpv) using PCV2b (or a 
      combination of PCV2a and PCV2b), porcine reproductive and respiratory syndrome 
      virus (PRRSV), and porcine parvovirus (PPV) to mimic what commonly occurs in the 
      field. The experiment was terminated 21 days post challenge (dpc) or 49dpv. Pigs 
      vaccinated with the chimeric PCV1-2b vaccine had significantly higher levels of 
      PCV1-2b viremia and shedding of the PCV1-2b vaccine virus in feces and nasal 
      secretions but also a more robust humoral immune response as evidenced by 
      significantly higher ELISA S/P ratios compared to the PCV1-2a vaccination. 
      Regardless of challenge, the PCV1-2b vaccination significantly reduced the 
      prevalence and amount of PCV2 viremia compared to the PCV1-2a vaccination. 
      Interestingly, in the non-vaccinated pigs concurrent PCV2a infection resulted in 
      clinical disease and increased macroscopic lung lesions compared to pigs 
      challenged with PCV2b alone, further supporting the idea that concurrent 
      PCV2a/PCV2b infection is necessary for optimal PCV2 replication.
CI  - Copyright (c) 2012 Elsevier Ltd. All rights reserved.
FAU - Opriessnig, Tanja
AU  - Opriessnig T
AD  - Department of Veterinary Diagnostic and Production Animal Medicine, College of 
      Veterinary Medicine, Iowa State University, Ames, IA, USA. tanjaopr@iastate.edu
FAU - O'Neill, Kevin
AU  - O'Neill K
FAU - Gerber, Priscilla F
AU  - Gerber PF
FAU - de Castro, Alessandra M M G
AU  - de Castro AM
FAU - Gimenez-Lirola, Luis G
AU  - Gimenez-Lirola LG
FAU - Beach, Nathan M
AU  - Beach NM
FAU - Zhou, Lei
AU  - Zhou L
FAU - Meng, Xiang-Jin
AU  - Meng XJ
FAU - Wang, Chong
AU  - Wang C
FAU - Halbur, Patrick G
AU  - Halbur PG
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121119
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Antibodies, Viral)
RN  - 0 (Vaccines, Attenuated)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Animals
MH  - Antibodies, Viral/blood
MH  - Blood/virology
MH  - Bodily Secretions/virology
MH  - Circoviridae Infections/immunology/prevention & control/*veterinary
MH  - Circovirus/genetics/*immunology
MH  - Coinfection/prevention & control/veterinary/virology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Feces/virology
MH  - Genotype
MH  - Parvoviridae Infections/prevention & control/veterinary
MH  - Parvovirus, Porcine/immunology
MH  - Swine
MH  - Swine Diseases/immunology/*prevention & control
MH  - Vaccines, Attenuated/administration & dosage/immunology
MH  - Viral Load
MH  - Viral Vaccines/administration & dosage/*immunology
MH  - Viremia/*prevention & control
MH  - Virus Shedding
EDAT- 2012/11/24 06:00
MHDA- 2013/05/31 06:00
CRDT- 2012/11/24 06:00
PHST- 2012/07/05 00:00 [received]
PHST- 2012/10/16 00:00 [revised]
PHST- 2012/11/09 00:00 [accepted]
PHST- 2012/11/24 06:00 [entrez]
PHST- 2012/11/24 06:00 [pubmed]
PHST- 2013/05/31 06:00 [medline]
AID - S0264-410X(12)01623-4 [pii]
AID - 10.1016/j.vaccine.2012.11.030 [doi]
PST - ppublish
SO  - Vaccine. 2013 Jan 7;31(3):487-94. doi: 10.1016/j.vaccine.2012.11.030. Epub 2012 
      Nov 19.